

Name:

Ghulam Basit Mahesar

Designation:

postgraduate trainee gastroenterology

Institute:

Jinnah postgraduate medical centre,

City:

karachi sindh

Phone:

03313699724

Email Address:

drbasit83@gmail.com

Topic:

FREQUENCY AND CLINICAL RESPONSE OF SOFOSBUVIR, DACLATASVIR AND RIBAVIRIN IN PATIENTS OF CHRONIC HEPATITIS C UNDERGOING HEMODIALYSIS.

All Authors:

Ghulam Basit, Nazish Butt, Muhammad Ali, Abdul Manan

Abstract:

Background/Aims: HCV Infection is the most common and associated with significant morbidity and mortality in the hemodialysis patients. Directly acting antivirals (DAAs) has revolutionized the management of hepatitis C with Sofosbuvir as a main component of regimen. Our limited local data exist regarding its efficacy in end stage renal disease patients on dialysis specially in this part of the world. The aim of study is to determine the frequency of Hep C and efficacy of sofosbuvir, daclatasvir and ribavirin in patients on maintenance hemodialysis. Methods: This is a cross sectional study of HCV patients on hemodialysis. Efficacy was assessed by Sustained virologic response (SVR). Results: The study consisted of 88 regular hemodialysis patients out of which 30 were found Hep. C positive. Classified as Genotype 1 (GT-1) 13 and as Genotype 3 (GT-3) 17. The mean age of study population was 35±5 years. Males were (n=18) and Females were (n=12). In GT-1, treatment naive patients are nine and SVR achieved in 7 pts and ETR in 2 pts. In treatment experienced group total 4 patients GT-1, in which 3 pts achieved SVR and 1 ETR. In GT-3, treatment naive 15 pts, 11 achieved SVR and 4 pts RVR achieved. GT-3 treatment experienced two patients achieved SVR. Conclusion: We have found Hep. C in 30/88 Dialysis patients with frequency of (34.0%). SOF+DAC+RIB are effective for treatment naive and treatment experienced patients on hemodialysis. Out of 30 HEP.C patients, 23 patients have achieved SVR with frequency of (76.66%), while 7 patients achieved ETR/RVR. (GT-1) total 13 patients, in which SVR achieved in (76.92%) and (GT-3) total 17 Patients and SVR achieved in (76.47%). While others achieved ETR/RVR.